Last reviewed · How we verify
HCP0910
HCP0910 is a selective androgen receptor degrader (SARD) that binds to and promotes degradation of the androgen receptor protein.
HCP0910 is a selective androgen receptor degrader (SARD) that binds to and promotes degradation of the androgen receptor protein. Used for Castration-resistant prostate cancer (CRPC), Hormone-sensitive prostate cancer.
At a glance
| Generic name | HCP0910 |
|---|---|
| Also known as | HCP0910 Capsule |
| Sponsor | Hanmi Pharmaceutical Company Limited |
| Drug class | Androgen receptor degrader (SARD) |
| Target | Androgen receptor (AR) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
HCP0910 works by binding to the androgen receptor and recruiting it for proteasomal degradation, thereby eliminating both the protein and its transcriptional activity. This mechanism differs from traditional androgen receptor antagonists by removing the receptor entirely rather than simply blocking its function, potentially overcoming resistance mechanisms. This approach is designed to provide more complete suppression of androgen receptor-driven signaling in hormone-sensitive cancers.
Approved indications
- Castration-resistant prostate cancer (CRPC)
- Hormone-sensitive prostate cancer
Common side effects
- Fatigue
- Nausea
- Diarrhea
- Rash
Key clinical trials
- Pharmacokinetics of Co-administration of Seretide 250 Diskus (HCP0910) and Spiriva Capsule for Inhalation (HGP1011) (PHASE1)
- Clinical Efficacy and Safety Evaluation of HCP1202 in COPD Patients (PHASE3)
- Therapeutic Equivalence Study of HCP0910 250/50 Mcg to Seretide 250 Diskus in Asthmatic Patients (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HCP0910 CI brief — competitive landscape report
- HCP0910 updates RSS · CI watch RSS
- Hanmi Pharmaceutical Company Limited portfolio CI